Aspen News Today | 2 Min News | The Daily News Now!
Colorado’s bold move to cap prescription drug prices is under legal fire, with Amgen suing over its cap on Enbrel—a drug that brought in over $2 billion. A federal judge now weighs whether the state’s Prescription Drug Affordability Board violates federal patent law, amid confusion over how drug pricing really works and whether price caps truly hurt innovation or just shift costs around. The ruling could set a national precedent for how states tackle skyrocketing drug costs. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/c66f412ce3c22e35
441 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de Aspen News Today | 2 Min News | The Daily News Now!!